DELAYED NEGATIVE SYMPTOM RESPONSE TO ANTIPSYCHOTICS: AN INDIVIDUAL PARTICIPANT DATA ANALYSIS

Study Protocol & Statistical Analysis Plan

Stefan Leucht
Evidence-Based Medicine in Psychiatry and Psychotherapy
Technical University of Munich
stefan.leucht@tum.de

Mathias Harrer
Evidence-Based Medicine in Psychiatry and Psychotherapy
Technical University of Munich
mathias.harrer@tum.de

Susan Illing
Evidence-Based Medicine in Psychiatry and Psychotherapy
Technical University of Munich
susan.illing@mri.tum.de

Stephen Z. Levine
School of Public Health
University of Haifa
slevine@univ.haifa.ac.il

June 9th, 2025 (Version 1)
January 5th, 2026 (Version 2)

Summary

This protocol outlines an individual participant data (IPD) analysis investigating the temporal dynamics of schizophrenia symptoms during antipsychotic treatment. Using harmonized data from six antipsychotic drug trials, we aim to examine weekly trajectories of Positive and Negative Syndrome Scale (PANSS) sub-scores over a 26-week period. Our aim is to determine whether reductions in positive symptoms precede and predict improvements in negative symptoms. To this end, will conduct (i) descriptive analyses, showing the trajectories of five PANSS sub-scores over time; (ii) test potential a "delay" until response in negative symptoms (versus positive symptoms) is reached; and (iii) examine if improvements in positive symptoms predict changes in negative symptoms one week ahead.

Background & Aims

The aim of this individual participant data (IPD) analysis is to examine the trajectory of schizophrenia symptoms during antipsychotic treatment. Antipsychotic drugs are believed to only improve positive (delusions, hallucinations), but not the negative symptoms of schizophrenia. However, in randomised, double-blind trials comparing antipsychotic drugs with placebo (Leucht, Arbter et al., 2009) and comparing antipsychotic drugs head-to-head (Leucht, Corves, et al., 2009; Huhn et al., 2019) both positive and negative symptoms improve, even with high-potency, first-generation D_2 blockers such as haloperidol. One hypothesis is that the improvement of negative symptoms comes after the improvement of positive symptoms in the following way: patients suffering from hallucinations and delusions are so concerned by their symptoms that they do not interact with other people. When positive symptoms are improved by antipsychotic drugs, these negative symptoms will improve as well. We will harness IPD from six large-scale clinical trials comparing the effects of olanzapine or amisulpride for acute schizophrenia. This study aims to assess whether reductions in positive symptoms precede and are associated with subsequent improvements in negative symptom burden over time.

Eligibility criteria

Individual participant data (IPD) for this study are drawn from six large-scale randomized trials of antipsychotic treatment (Breier et al., 2005; Colonna et al., 2000; Kahn et al., 2008; Lieberman et al., 2003; Sechter et al., 2002; Tran et al., 1997). These IPD have previously been used in analyses by our group (Leucht et al., 2007; Beitinger et al., 2008; Levine & Leucht, 2012; Levine & Leucht, 2010). Participants are included if they meet the following criteria: (i) a diagnosis of acute schizophrenia (paranoid, disorganized, or undifferentiated type), schizophreniform disorder, or schizoaffective disorder according to DSM-III-R through DSM-5; (ii) received therapeutically active doses of second-generation antipsychotics, as defined by Gardner et al. and McAdams et al.; (iii) were treated with second-generation antipsychotics only. In trials where multiple second-generation antipsychotics were studied, we will select the agent associated with the lowest risk of extrapyramidal side effects, based on findings by Huhn et al. (2019). This is because extrapyramidal symptoms such as parkinsonism and akinesia can mimic negative symptoms, thereby confounding the analysis. For the same reason, first-generation dopamine D_2 receptor antagonists, such as haloperidol, are excluded. Additionally, we will exclude all participants who received (i) placebo or (ii) "pseudo-placebo" treatments, i.e., clearly sub-therapeutic doses of antipsychotics. To ensure comparability of follow-up assessments, and because no substantial further effects of acute antipsychotic treatment are expected beyond six months, we will restrict all analyses to outcome data from the first 26 weeks (6 months) of treatment in our main analysis.

Study identification & selection

Studies were identified through a systematic search of the EBMPP Data Warehouse (ebmpp.org/helpful-tools/warehouse), which hosts a harmonized collection of antipsychotic trial data.

Risk of bias assessment

Risk of bias of the included studies will be evaluated using domains of the Cochrane Risk of Bias (RoB 2) tool (Sterne et al., 2019): randomisation process, deviation from the intervention, missing outcome data, measurement of the outcome, and selection of the reported results.

Data harmonization

In each study, measures of the Positive and Negative Symptoms Scale (PANSS; Kay et al., 1987) will be transformed into five subscores based on the consensus model proposed by Wallwork et al. (2012). This model classifies 20 original PANSS items into five distinct factors: positive, negative, disorganized/concrete, excited, and depressed. Adopting this structure will allow us to represent the multidimensional structure of schizophrenia while maintaining a high level of comparability within the research domain. One otherwise eligible study (Colonna et al., 2000) provided individual item scores only for PANSS items 1 to 14. To approximate the five-factor scores for this study, missing items will be supplemented with corresponding items from the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962). As a result, two factors will be fully reconstructed, and three remain incomplete, with one missing item each.

Missing data handling

Primary analyses will be conducted in the observed data. As a sensitivity analysis, missing data will also be addressed using multiple imputation by fully conditional specification (MICE algorithm; Buuren & Groothuis-Oudshoorn, 2011), under the missing-at-random (MAR) assumption. To assess the plausibility of the MAR assumption, exploratory analyses will be conducted, including visualizations of imputed values and examination of missingness patterns. Multilevel imputation models with homoscedastic errors will be used to account for the nesting of measurements within patients and trials. Highly collinear variables and variables with systematically missing data ("structural zeros") will be excluded from the imputation model. Predictive mean matching will be used as the default imputation method. A total of $m = 25$ imputed datasets will be generated. Analysis models will be fitted in each dataset, and parameter estimates will be combined using Rubin's rules.

Statistical analyses

To characterize the dataset, we will analyze weekly scheduled visits across the five PANSS sub-scales using descriptive statistics. For each study and for the pooled data, we will calculate and visualize (i) the weekly mean subscale score and its standard deviation, (ii) the mean absolute change per subscale, (iii) the weekly mean change relative to the baseline values (expressed as a percentage), and (iv) the mean cumulative change from baseline over six months as a percentage of the baseline value.

To examine the possibility of a delayed response in negative symptoms following antipsychotic treatment, we will define a 50% reduction on each Wallwork subscale as a treatment response. For each participant, we will determine the week in which this response criterion is first met, yielding time-to-event data (which may be right-censored). Based on these data, we will calculate the median time-to-response in weeks for each subscale, and test differential response times using mixed-effects Cox regression models that account for clustering at the study level.

To investigate whether improvements in positive symptoms are mediated by improvements in other symptom domains, we will employ path analyses based on structured equation modeling (SEM). Specifically, we will estimate direct, indirect, and total path effects over six months. Additionally, we will conduct path analyses with negative symptoms as the outcome.

Sensitivity analyses

We will conduct several sensitivity analyses to assess the robustness of our findings. First, where applicable, we will repeat all primary analyses using multiply imputed data (see "missing data handling" section). Second, we will repeat all analyses when only haloperidol arms are excluded due to its pronounced extrapyramidal symptoms risk. Third, we will rerun all analyses using only the subset of trials with outcome data available up to one year (52 weeks). Fourth, we will rerun time-to-response analyses using a 25% symptom reduction as the response criterion for each Wallwork subscale. Fifth, we will also investigate a shorter period of six weeks in the path analyses.

Current status

This protocol and statistical analysis plan (SAP) was registered after identifying and harmonizing eligible data, but prior to conducting any statistical analyses. The table below provides an overview of the antipsychotic trials in the current IPD, including study characteristics and eligible sample sizes for the present analysis.

Study	Medication (Dose)	N (Included)	Inclusion Criteria & Exclusion Criteria	Country	Assessments (Weeks)
Breier et al., 2005	Olanzapine 10-20mg	277	*Inclusion*: Diagnosis of schizophrenia (DSM-IV); in- and outpatients; BPRS baseline score >= 42, PANSS score >= 4 on at least one positive symptom item and a CGI severity of illness score >= 4. *Exclusion*: Participation in clinical trial of another drug within 1m before study entry; treatment with injectable depot antipsychotic within one treatment cycle before study entry; treatment with clozapine within 7d before enrollment; treatment with olanzapine or ziprasidone within 6m of study start and treatment withdrawal because of clinically important and/or intolerable adverse events or lack of treatment response; congenital long QT syndrome; QTc interval longer than 500 msec, or any ECG abnormality that would confound measurement of the QT interval; substance dependence (DSM-IV) within past month; serious/unstable illness.	Argentina, Austria, Brazil, Germany, Great Britain, Ireland, Mexico, Peru, Puerto Rico, Spain, USA, Venezuela	0, 1, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, 24
Colonna et al., 2000	Amisulpride 200-800mg	368	*Inclusion*: Diagnosis of subchronic or chronic schizophrenia with acute exacerbation (DSM-III-R) of the paranoid, disorganised or undifferentiated type; BPRS score >= 4 on at least two positive items. *Exclusion*: Schizophreniform or schizoaffective disorder, maniac or excitative depressive states, and severe cardiovascular disease, Parkinson`s disease or phaeochromocytoma.	Belgium, France, Great Britain, Hungary, Italy, Latvia, Morocco, Slovenia, Spain	0, 1, 2, 4, 13, 26
Kahn et al., 2008	Amisulpride 200–800mg, Olanzapine 5–20mg	105	*Inclusion*: Diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder (DSM-IV) confirmed by the MINI plus *Exclusion*: More than 2y since the onset of positive symptoms; use of any antipsychotic drug for more than 2w in previous year, or for 6w at any time; known intolerance to one of the study drugs; contraindications for any of the study drugs.	Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain, Sweden, Switzerland	0, 2, 4, 6, 8, 12, 26
Lieberman et al., 2003	Olanzapine 5-10mg	131	*Inclusion*: Diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder (DSM-IV); onset of psychotic symptoms before age 35 years; psychotic symptoms (delusions, hallucinations, thought disorder, and grossly bizarre behavior) for at least 1m but not more than 60m; PANSS score >= 4 on at least two psychosis items or score >= 5 on one psychosis item; CGI severity score >= 4; required treatment with antipsychotic drugs on a clinical basis *Exclusion*: Previously antipsychotic drug treatment for more than 16 cumulative weeks; treatment with clozapine at anytime in lifetime, or treatment with an injectable depot neuroleptic within less than three dosing intervals before study entry; pregnancy or lactation, or no adequate use of contraception; serious, unstable medical illnesses or findings from a medical examination that suggested a contraindication to antipsychotic drug treatment; history of allergic or severe adverse reactions to study medications; diagnosis of substance dependence (DSM-IV) (except caffeine and nicotine) within 1m before first visit; serious suicidal risk; required treatment with anticonvulsants, benzodiazepines (except as allowed for agitation and control of extrapyramidal signs), antidepressants, psychostimulants, or other antipsychotic drugs concurrently with study medications beyond those permitted as concomitant treatments; contraindications for neuroimaging per current regulations of the local regulatory agency; history of any DSM-IV psychotic disorder with recovery; premorbid IQ of <= 70; ECT within 1m before study entry	Canada, Great Britain, Netherlands, USA	0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24
Sechter et al., 2002	Amisulpride 400-1000mg	152	*Inclusion*: Diagnosis of chronic schizophrenia (disease duration of at least 2y) of the paranoid, disorganized, undifferentiated, or residual type (DSM-IV); PANSS total score of 60-120 and recent deterioration of clinical state needing a change in treatment; in- or outpatients *Exclusion*: Predominant negative symptoms (3 or more items >= 4 on the negative PANSS subscale and less than 3 items >= 4 on the positive PANSS; symptoms of substance-related withdrawal; cardiovascular disease, severe respiratory, hematologic or endocrinologic	Austria, Belgium, Estonia, France, Germany, Hungary, Latvia, Netherlands, Slovenia	0, 1, 2, 3, 4, 6, 8, 13, 17, 21, 26

			diseases, Parkinson's disease, phaeochromocytoma; significant abnormal laboratory tests, or a history of allergy or hypersensitivity to risperidone or benzarnides; current treatment with amisulpride or risperidone; no response to at least two well-validated antipsychotics; received lithium-based therapy in previous 10d; received long-acting antipsychotics (if the usual interval between two injections had not elapsed before inclusion); pregnancy or lactation, and women of childbearing age not using adequate contraception		
Tran et al., 1997	Olanzapine 10-20mg	172	*Inclusion*: Diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder (DSM-IV); BPRS score >= 42; in- or outpatients *Exclusion*: Comorbid or other recent major axis I disorders; pregnancy or lactation; serious medical illnesses in which pharmacotherapy posed a substantial risk or confounded diagnosis; failed to show at least minimal clinical response with at least three antipsychotics for at least 6w.	Belgium, France, Germany, Great Britain, Netherlands, South Africa, Spain, Switzerland	0, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24

The following decisions were made for drug choice:

- In Breier et al. (2005), Kahn et al. (2008) and Tran et al. (1997), we chose olanzapine and amisulpride rather than ziprasidone or risperidone because of their lower EPS risk according to Huhn et al. (2019).
- For the same reason, amisulpride was preferred to risperidone in Sechter et al. (2002).
- Olanzapine was preferred to quetiapine in Kahn et al. (2008), because in Huhn et al. (2019) the EPS risk is the same, but olanzapine has consistently been shown to be a more efficacious drug (Huhn et al. 2019, Leucht et al., 2013; Taipale et al., 2018).
- Haloperidol arms were generally excluded (see "Eligibility criteria").

■

References

Beitinger, R., Lin, J., Kissling, W., & Leucht, S. (2008). Comparative remission rates of schizophrenic patients using various remission criteria. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *32*(7), 1643-1651.

Breier, A., Berg, P. H., Thakore, J. H., Naber, D., Gattaz, W. F., Cavazzoni, P., Walker, D. J., Roychowdhury, S. M., & Kane, J. M. (2005). Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. *American Journal of Psychiatry*, *162*(10), 1879–1887. https://doi.org/10.1176/appi.ajp.162.10.1879

Buuren, S. van, & Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*, *45*, 1–67. https://doi.org/10.18637/jss.v045.i03

Colonna, L., Saleem, P., Dondey-Nouvel, L., Rein, W., & Group, A. S. (2000). Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. *International Clinical Psychopharmacology*, *15*(1), 13–22.

Han, S., & Zhou, X.-H. (2023). Defining estimands in clinical trials: A unified procedure. *Statistics in Medicine*.

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., ... & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *The Lancet*, *394*(10202), 939-951.

Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., & Libiger, J. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. *The Lancet*, *371*(9618), 1085–1097.

Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin*, *13*(2), 261–276.

Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *The Lancet*, *382*(9896), 951-962.

Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. *Molecular Psychiatry*, *14*(4), 429-447.

Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *The Lancet*, *373*(9657), 31-41.

Levine, S. Z., & Leucht, S. (2010). Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. *Biological Psychiatry*, *68*(1), 86-92.

Levine, S. Z., & Leucht, S. (2012). Delayed-and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. *European Neuropsychopharmacology*, *22*(11), 812-817.

Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., Wei, H., Hamer, R. M., & the HGDH Study Group. (2003). Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol. *American Journal of Psychiatry*, *160*(8), 1396–1404. https://doi.org/10.1176/appi.ajp.160.8.1396

Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. *Psychological Reports*, *10*(3), 799–812. https://doi.org/10.2466/pr0.1962.10.3.799

Sechter, D., Peuskens, J., Fleurot, O., Rein, W., Lecrubier, Y., & Group, A. S. (2002). Amisulpride vs. risperidone in chronic schizophrenia: Results of a 6-month double-blind study. *Neuropsychopharmacology*, *27*(6), 1071–1081.

Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., & Eldridge, S. M. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ*, *366*.

Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *Journal of Clinical Psychopharmacology*, *17*(5), 407–418.

Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J. (2018). Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. *Schizophrenia bulletin*, *44*(6), 1381-1387.

Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. (2012). Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. *Schizophrenia Research*, *137*(1–3), 246–250.